This study aims to study the effect of cromakalim on experimentally induced convulsion in albino rats using maximal electro-shock (MES) & pentylenetetrazol (PTZ) induced seizure models. For this study 100 albino rats of either sex weighing 100 to 150 grams were divided into 10 equal groups, 5 groups were used for each model. Rats of group 1 in both models received placebo (0.5ml of distilled water) intraperitoneally (ip), while groups 2,3 and 4 of both the models were administered three doses of cromakalim, i.e. 0.25, 0.5 and 1 mg/kg ip respectively. Rats of group 5 received phenytoin 40 mg/kg ip in the MES model and ethosuximide 100mg/kg ip in PTZ model, which served as positive controls respectively. In MES model, 150mAmp current was administered by electro-convulsiometer through ear electrodes to rats and presence of hind limb extension was recorded as the end-point, at different time intervals. In the second model, PTZ was administered at the dose of 60mg/kg ip, 60mins after cromakalim/ control drug pre-treatment. Onset and duration of clonic convulsion was recorded. In MES induced seizure model, cromakalim at the doses of 0.5 and 1 mg produced significant protective effect which was comparable to phenytoin 40mg/kg. In PTZ induced seizure model, cromakalim pretreatment in the dose of 0.25mg increased onset time, decreased duration of convulsion in 70% of animals, while the doses of 0.5 and 1 mg/kg had significant anticonvulsant activity comparable to ethosuximide 100mg/kg. Cromakalim possesses significant anticonvulsant property both on electroshock and chemoshock induced seizure models.
Introduction
Epilepsy is a chronic convulsive disorder characterised by periodic, unpredictable and paroxysmal occurrence of seizure and has a poor prognosis. The available antiepileptic drugs control the fits in only two-third of patients after years of continued therapy, which is usually associated with diverse complications and manifestations of toxicity 1 . The rest may remain uncontrolled or partially controlled and have to bear the ordeal of protracted therapy with multiple antiepileptic drugs, at the cost of suffering from iatrogenic complications. Hence, the search for the ideal antiepileptic drugs continues 2 . Almost all antiepileptic drugs act by preventing neuronal discharge which produce seizure. Though the neurophysiological and biochemical mechanism at cellular or sub-cellular level affected by the different
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dr.anjalitarai@gmail.com drugs may be diverse, their ultimate effect is to stabilise the neuronal membranes against the onslaught of abnormal epileptic discharge and suppress neuronal hyperexcitability 3 .The K + channel openers like nicorandil, cromakalim, pinacidil, diazoxide and minoxidil are a group of drugs which produce stabilizing action on cell membranes through membrane hyperpolarisation via increased transmembrane K + conductance 4 
Experimental animals
Healthy albino rats weighing 150 to 250 gms, of either sex, housed in the Departmental animal house were used for this study. The animals were preliminarily screened for the occurrence of convulsions on induction, and those which responded positively to the respective stimuli, were included into the study. Fifty such animals were selected and divided into 5 equal groups for MES test, and another fifty rats were selected for PTZ test. They were housed in separate polypropylene cages (10 in each group) and maintained at a temperature of 28±1ºC and relative humidity 45-55%, in a 12:12 light: dark cycle. They were fed with standard diet and given water ad libitum, food was withdrawn 6hrs before and during experimentation, which was performed during 1200-1400hr. The study protocol was approved by the Institutional animal ethics committee. 
Drugs and Chemicals

Result
Cromakalim in the dose of 0.25 mg/kg had no effect on MES induced seizure at all the observation periods, similar to that observed with normal saline (placebo) treated group. Cromakalin in doses of 0.5 and 1.0 mg /kg, prevented tonic hind limb extension of rats in the MES test, at all times of observation i.e. 30, 60, 90 and 120 mins of drug administration (Table -1 , Fig 1) . These effects were similar to that observed with phenytoin 40mg/kg, as there was no statistical difference between the protective action of the two higher doses of cromakalim and phenytoin (P < 0.05). Maximum protection (100%) was observed at 60mins, with both the drugs. In the PTZ administered rats, convulsion occurred in 100% animals, in the normal saline treated group. In the rats pretreated with cromakalim 0.25 mg/kg, convulsion occurred in only 30% of animals and the onset of convulsion was delayed appearing after 7 mins (of PTZ inj.) in comparison to after 3.16 mins in the normal saline treated group. There was no significant difference in the duration of clonic convulsion. There occurred complete abolition of PTZ induced seizure in the rats treated with cromakalim 0.5 and 1.0 mg/kg ( Table 2 , Fig 2) . Ethosuximide (100 mg/kg) prevented seizure induced by the chemo-convulsant pentylenetetrazol in 100% of animals. The effects seen with the two higher doses of cromakalim was statistically similar to that observed by ethosuximide. No mortality was however observed in any of the groups.
Discussion
The potassium channel openers induce hyperpolarization through potassium efflux, and by stabilizing the cell membrane might raise the seizure threshold. 
Conclusion
Hence, cromakalim possesses significant anticonvulsant activity against tonic-clonic and absence seizures models in animals. The anti-seizure activity is comparable to phenytoin in MES model and ethosuximide in the PTZ model. Further controlled studies are necessary using other models of convulsion for establishing the anti-epileptic property of cromakalim and confirming its mechanism of action. 
